Patents by Inventor Adam G. Kreutzer

Adam G. Kreutzer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Cyclic peptides, methods of synthesis, and methods of treatment
    Patent number: 11753447
    Abstract: Cyclic peptide compounds and methods of their synthesis are provided. Formulations and medicaments are also provided that are directed to the treatment of coronavirus. Therapeutics are also provided containing a therapeutically effective dose of one or more cyclic peptide compounds, present either as pharmaceutically effective salt or in pure form, including, but not limited to, formulations for oral, intravenous, or pulmonary administration.
    Type: Grant
    Filed: July 30, 2021
    Date of Patent: September 12, 2023
    Assignee: The Regents of the University of California
    Inventors: Adam G. Kreutzer, James S. Nowick
  • Synthetic beta-amyloid peptides capable of forming stable antigenic oligomers
    Patent number: 11319348
    Abstract: Synthetic A? peptides, oligomers, their methods of synthesis, and their applications are provided. The A? peptides can form stable, soluble oligomers important for the advancement of knowledge, detection, and treatment of Alzheimer's disease. Antibodies specific to oligomeric A? and their methods of synthesis are also described.
    Type: Grant
    Filed: April 13, 2020
    Date of Patent: May 3, 2022
    Assignee: The Regents of the University of California
    Inventors: James S. Nowick, Adam G. Kreutzer, Ryan K. Spencer, Patrick J. Salveson
  • Cyclic Peptides, Methods of Synthesis, and Methods of Treatment
    Publication number: 20220033444
    Abstract: Cyclic peptide compounds and methods of their synthesis are provided. Formulations and medicaments are also provided that are directed to the treatment of coronavirus. Therapeutics are also provided containing a therapeutically effective dose of one or more cyclic peptide compounds, present either as pharmaceutically effective salt or in pure form, including, but not limited to, formulations for oral, intravenous, or pulmonary administration.
    Type: Application
    Filed: July 30, 2021
    Publication date: February 3, 2022
    Applicant: The Regents of the University of California
    Inventors: Adam G. Kreutzer, James S. Nowick
  • Synthetic Beta-Amyloid Peptides Capable of Forming Stable Antigenic Oligomers
    Publication number: 20200347099
    Abstract: Synthetic A? peptides, oligomers, their methods of synthesis, and their applications are provided. The A? peptides can form stable, soluble oligomers important for the advancement of knowledge, detection, and treatment of Alzheimer's disease. Antibodies specific to oligomeric A? and their methods of synthesis are also described.
    Type: Application
    Filed: April 13, 2020
    Publication date: November 5, 2020
    Applicant: The Regents of the University of California
    Inventors: James S. Nowick, Adam G. Kreutzer, Ryan K. Spencer, Patrick J. Salveson
  • Synthetic beta-amyloid peptides capable of forming stable antigenic oligomers
    Patent number: 10662226
    Abstract: Synthetic A? peptides, oligomers, their methods of synthesis, and their applications are provided. The A? peptides can form stable, soluble oligomers important for the advancement of knowledge, detection, and treatment of Alzheimer's disease. Antibodies specific to oligomeric A? and their methods of synthesis are also described.
    Type: Grant
    Filed: October 26, 2017
    Date of Patent: May 26, 2020
    Assignee: The Regents of the University of Caiifomia
    Inventors: James S. Nowick, Adam G. Kreutzer, Ryan K. Spencer, Patrick J. Salveson
  • Synthetic Beta-Amyloid Peptides Capable of Forming Stable Antigenic Oligomers
    Publication number: 20180118790
    Abstract: Synthetic A? peptides, oligomers, their methods of synthesis, and their applications are provided. The A? peptides can form stable, soluble oligomers important for the advancement of knowledge, detection, and treatment of Alzheimer's disease. Antibodies specific to oligomeric A? and their methods of synthesis are also described.
    Type: Application
    Filed: October 26, 2017
    Publication date: May 3, 2018
    Applicant: The Regents of the University of California
    Inventors: James S. Nowick, Adam G. Kreutzer, Ryan K. Spencer, Patrick J. Salveson